Search results
Results from the WOW.Com Content Network
In January 2016, the company received an investment from the Bill & Melinda Gates Foundation's Strategic Innovation Fund to support the development of antimalarial medication based on semi-synthetic artemisinin. [8] In April 2019, the company raised $34-million in private placement of its common stock and warrants.
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
In 2015, the UK had around 225 main biotechnology companies, turning over around £2.9bn. [2] Exports accounted for around £1.5bn of turnover. The UK has an estimated 5% share of the global market. In Europe, by patent applications submitted under the Patent Cooperation Treaty, the UK is third, second to Germany and France but seventh in the ...
70% of the investments in life sciences in Europe are made in the United Kingdom, Germany, Ireland, the Netherlands, France, and Switzerland. [4] [5] In addition to pharmaceutical companies (65 companies), Switzerland is home to many companies in the fields of biotechnology (338 companies) or medical devices and technology (341 companies).
Venter (and Smith)'s previous company, Celera Genomics, was a driving force in the race to sequence the human genome. [9] The firm takes its name from the phrase synthetic genomics which is a scientific discipline of synthetic biology related to the generation of organisms artificially using genetic material. [10] [11]
When completed, the facility will be one of the world's largest plants supporting single-use bioreactors and will help accelerate the development of biologic drugs in Europe. [24] MFG6 will have a perfusion bioreactor capacity of 6,000 liters in a continuous bioprocessing configuration and MFG7 will have a 48,000 liter bioreactor capacity in a ...
The field of synthetic biology has not been good to investors. But maybe we've just been looking in the wrong places. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, [3] headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology.